For East Asian patients with ATTR-CM, Amvuttra is safe, extends survival

For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with significant long-term benefits.

Those are the findings of a new data analysis from the Phase 3 HELIOS-B study (NCT04153149), a global clinical trial designed to assess the treatment’s effects over nearly three years in more than 650 people with ATTR-CM. This subgroup analysis specifically looked at Amvuttra use among participants from South Korea and Japan.